1. Angiotensin as a Vasopressor in Vasodilatory Shock

2. Background: Defining Shock

3. Types of Shock

4. Causes of Vasodilatory Shock

5. Pathophysiology of Vasodilatory Shock

6. Hemodynamic Profiles of Types of Shock

7. Homeostasis Systems Involved in Restoring Effective BP

8. Vasodilatory Shock Goals of Treatment

9. Vasodilatory Shock Treatment Strategies

10. Management of Vasodilatory Shock

11. Fluid Therapy as Initial Strategy

12. Recommendations for Vasoactive Medications

13. VASST Study

14. Predictors of Response to Vasopressin in Adults With Septic Shock

15. Outcomes Associated With the Use of Catecholamines for the Treatment of Hypotension in Patients With Shock

16. Vasopressor Dose Requirement

17. ADRENAL Trial

18. Study: Hydrocortisone and Fludrocortisone in Patients With Septic Shock

19. Selepressin

20. Effects of the V1a Agonist FE 202158 in Patients With Septic Shock (Phase 2a)

21. Selepressin Evaluation Program for SEPSIS-ACT

22. Angiotensin II

23. Restoration of Effective Blood Pressure

24. Mechanism of Action of Angiotensin II

25. Angiotensin II Trials

26. ATHOS-3 Primary Outcome

27. ATHOS-3 Additional Endpoints

28. Ang II Responders Survival by Ang I:Ang II Ratio at Baseline

29. Low ACE, High Ang I/Ang II

30. Angiotensin II: Current Status

31. Take-Home Messages

32. Abbreviations

33. Abbreviations (cont)